MARKET

AVR

AVR

ANTERIS TECHNOLOGIES GLOBAL
NASDAQ
9.69
-0.19
-1.92%
After Hours: 9.69 0 0.00% 16:43 06/26 EDT
OPEN
9.97
PREV CLOSE
9.88
HIGH
10.26
LOW
9.49
VOLUME
4.67M
TURNOVER
--
52 WEEK HIGH
10.56
52 WEEK LOW
2.850
MARKET CAP
943.25M
P/E (TTM)
-4.3826
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Anteris Technologies Global Corp. (AVR) and Kymera Therapeutics (KYMR)
TipRanks · 2d ago
Weekly Report: what happened at AVR last week (0615-0619)?
Weekly Report · 6d ago
Analysts Conflicted on These Healthcare Names: Anteris Technologies Global Corp. (AVR), Lifecore Biomedical (LFCR) and Biogen (BIIB)
TipRanks · 06/18 12:30
Weekly Report: what happened at AVR last week (0608-0612)?
Weekly Report · 06/15 09:04
ANTERIS TECHNOLOGIES GLOBAL - RECEIVES FRENCH REGULATORY CLEARANCE FOR DURAVR PARADIGM GLOBAL PIVOTAL TRIAL
Reuters · 06/08 22:31
Anteris Technologies cleared by ANSM for DurAVR THV trial
TipRanks · 06/08 10:12
Anteris Technologies Receives Full Regulatory Clearance From The French National Agency For Medicines And Health Products Safety For The DurAVR Transcatheter Heart Valve Global Pivotal Trial In Patients With Severe Calcific Aortic Stenosis
Benzinga · 06/08 10:10
ANTERIS TECHNOLOGIES GLOBAL - RECEIVES FRENCH REGULATORY CLEARANCE FOR DURAVR TRANSCATHETER HEART VALVE GLOBAL TRIAL
Reuters · 06/08 10:02
More
About AVR
Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company's ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.

Webull offers Anteris Technologies Global Corp stock information, including NASDAQ: AVR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AVR stock methods without spending real money on the virtual paper trading platform.